a gene therapy that targets degenerative neurological/rare diseases, etc
Optimizing Codon/promoter to increase efficiency
01Adoption of our self-developed AAV vector that is
delivered specifically to cells/tissues
Process & analytical development through our
in-house process development lab
The key to gene therapy is the safe arrival of the gene into the target tissue
CARE™ will meet the tissue-specific demand for AAV capsid, which is required by the growth of the gene therapy tax market.
Directed evolution: Secured a Capsid library with
a diversity of about 10¹²
Rational design : InsightMiner™
02Based on SOP, secured the technology for
producing an AAV library
Secured over 60 vector candidates
including XOB-031